- Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian . . .
Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody–drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in the United
- ELAHERE® (mirvetuximab soravtansine-gynx) | HCP Website
ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens Select patients for therapy based on an FDA-approved test 1
- Mirvetuximab soravtansine - Wikipedia
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [1][4] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate [4][5]
- FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum . . .
On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc [now a part of AbbVie]) for adult patients with FRα positive,
- Mirvetuximab Soravtansine-Gynx Approved for Ovarian Cancer
Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation now have a new treatment option
- Mirvetuximab soravtansine Uses, Side Effects Warnings
What is mirvetuximab soravtansine? Mirvetuximab soravtansine is used to treat adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are no longer responding to platinum-based chemotherapy and have received 1 to 3 types of chemotherapy
- A review of mirvetuximab soravtansine-gynx in folate receptor alpha . . .
Key Points Mirvetuximab soravtansine-gynx, a novel antibody-drug conjugate approved in the US for folate receptor alpha–expressing platinum-resistant ovarian cancer (PROC), is the only agent to demonstrate an overall survival benefit compared to standard-of-care chemotherapy in PROC
- Mirvetuximab soravtansine-gynx (intravenous route) - Mayo Clinic
Mirvetuximab soravtansine-gynx injection is used to treat folate receptor-alpha (FRa) positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received 1 to 3 previous treatments
|